<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00388011</url>
  </required_header>
  <id_info>
    <org_study_id>MOR-002</org_study_id>
    <nct_id>NCT00388011</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intranasal Morphine for Pain After Bunion Surgery</brief_title>
  <official_title>Randomized, Double-Blind, Placebo and Comparator-Controlled, Dose-Response Trial of the Efficacy and Safety of Intranasal Morphine, Intravenous Morphine and Placebo in Patients With Moderate to Severe Pain Following Orthopedic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Javelin Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Javelin Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study designed to evaluate the efficacy and safety of Intranasal (IN) Morphine Nasal Spray
      (MNS075) 3.75 mg, 7.5 mg, 15 mg, and 30 mg, intravenous (IV) morphine 7.5 mg, or IN placebo
      in patients with moderate to severe post-surgical pain following orthopedic surgery. After
      initial dosing, up to six (6) doses of IN MNS075 7.5 mg or 15 mg for up to twenty-four (24)
      hours will be evaluated. The rescue dose remained the same for each.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diagnosis and Main Criteria for Inclusion:

      Healthy adult patients (18 to 76 years old), who scored PS-1 to PS-3 according to the
      American Society of Anesthesiologists Physical Status Classification System, requiring
      primary, unilateral, first metatarsal bunionectomy surgery alone or with ipsilateral
      hammertoe repair without additional collateral procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS Total Pain Relief 0-4 hours (TOTPAR4)</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other measures of pain relief</measure>
    <time_frame>Several time points</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">187</enrollment>
  <condition>Hallux Valgus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal morphine 3.75 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal morphine 7.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal morphine 15 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal morphine 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous morphine 7.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intranasal placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Morphine (MNS075) 3.75 mg</intervention_name>
    <description>Intranasal Morphine (MNS075) 3.75 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Morphine 7.5 mg</intervention_name>
    <description>Intravenous Morphine 7.5 mg</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal morphine (MNS075) 7.5 mg</intervention_name>
    <description>Intranasal morphine (MNS075) 7.5 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal morphine (MNS075) 15 mg</intervention_name>
    <description>Intranasal morphine (MNS075) 15 mg</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal morphine (MNS075) 30 mg</intervention_name>
    <description>Intranasal morphine (MNS075) 30 mg</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal placebo</intervention_name>
    <description>Intranasal placebo</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Requires primary unilateral first metatarsal bunionectomy surgery alone or with
             ipsilateral hammertoe repair under regional anesthesia. The patient requires
             collateral orthopedic surgical procedures other than ipsilateral hammertoe repair may
             not be enrolled into the study.

          -  18 years of age or older

          -  Moderate to severe pain within eight (8) hours following completion of the required
             bunionectomy surgery

        Exclusion Criteria:

          -  Allergy to shellfish

          -  Signs of nasal congestion, nasal polyps, mucosal lesions of the nostrils, postnasal
             drip of any etiology or any clinically significant nasal pathology that may affect the
             absorption of study medication or the assessment of safety.

          -  Chronic respiratory insufficiency such that treatment with an opioid analgesic is
             contraindicated

        Additional Inclusion/Exclusion Criteria May Apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas G Stoker, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jean Brown Research</affiliation>
  </overall_official>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2006</study_first_submitted>
  <study_first_submitted_qc>October 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2006</study_first_posted>
  <last_update_submitted>January 11, 2008</last_update_submitted>
  <last_update_submitted_qc>January 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Amy Cohen/Director, Clinical Operations</name_title>
    <organization>Javelin Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Post surgical pain</keyword>
  <keyword>Bunionectomy</keyword>
  <keyword>Hammer Toe Syndrome</keyword>
  <keyword>Morphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hallux Valgus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

